R&D | April 15, 2026
Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Scientists at the forum warned of an increasingly volatile health landscape
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The Stealth AXiS surgical navigation system was recently cleared by the US Food and Drug Administration (FDA) for cranial procedures in the United States
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
Subscribe To Our Newsletter & Stay Updated
